Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

- Chemical process enhances room temperature stability - - Provisional patent applications filed - PURCHASE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company”...
November 12, 2024 08:00 ET | Source: Annovis Bio, Inc.

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
August 30, 2023 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Participation in Upcoming September Conferences

PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by...
November 28, 2022 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

PURCHASE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the rationale and design of the Company’s ongoing...
June 23, 2022 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association - NEW YORK, June 23, 2022 (GLOBE...
January 10, 2022 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
November 30, 2021 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation

PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...